{"organizations": [], "uuid": "d43f8ea5501e8bdef40d95edb0a70731270115cf", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-celgene-says-expects-fy-2018-rev-t/brief-celgene-says-expects-fy-2018-rev-to-be-about-14-4-bln-to-14-8-bln-idUSASB0C05N", "country": "US", "domain_rank": 408, "title": "BRIEF-Celgene Says Expects FY 2018 Rev To Be About $14.4 Bln To $14.8 Bln", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-08T17:55:00.000+02:00", "replies_count": 0, "uuid": "d43f8ea5501e8bdef40d95edb0a70731270115cf"}, "author": "", "url": "https://www.reuters.com/article/brief-celgene-says-expects-fy-2018-rev-t/brief-celgene-says-expects-fy-2018-rev-to-be-about-14-4-bln-to-14-8-bln-idUSASB0C05N", "ord_in_thread": 0, "title": "BRIEF-Celgene Says Expects FY 2018 Rev To Be About $14.4 Bln To $14.8 Bln", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters staff", "sentiment": "none"}, {"name": "celgene corp", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "thomson reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "January 8, 2018 / 3:55 PM / Updated 8 minutes ago BRIEF-Celgene Says Expects FY 2018 Rev To Be About $14.4 Bln To $14.8 Bln Reuters Staff \nJan 8 (Reuters) - Celgene Corp: * SEES PRELIMINARY Q4 REVLIMID SALES $2,188 MILLION \n* ORATION ANNOUNCES PRELIMINARY 2017 UNAUDITED RESULTS AND 2018 FINANCIAL GUIDANCE * SEES Q4 2017 ADJUSTED EARNINGS PER SHARE ABOUT $2.00 * SEES FY 2017 GAAP EARNINGS PER SHARE $3.64 TO $4.19 * SEES Q4 2017 GAAP LOSS PER SHARE $0.09 TO $+0.46 * SEES FY 2018 REVENUE UP 12 PERCENT \n* SEES FY 2018 REVENUE ABOUT $14.4 BILLION TO $14.8 BILLION * SEES FY 2018 ADJUSTED EARNINGS PER SHARE $8.70 TO $8.90 * SEES FY 2020 REVENUE $19 BILLION TO $20 BILLION * SEES FY 2017 ADJUSTED EARNINGS PER SHARE ABOUT $7.44 \n* Q4 REVENUE $3.5 BILLION VERSUS I/B/E/S VIEW $3.46 BILLION * SEES PRELIMINARY Q4 OTEZLA SALES $371 MILLION \n* FY2017 EARNINGS PER SHARE VIEW $7.34, REVENUE VIEW $12.98 BILLION -- THOMSON REUTERS I/B/E/S \n* FY2018 EARNINGS PER SHARE VIEW $8.71, REVENUE VIEW $14.83 BILLION -- THOMSON REUTERS I/B/E/S \n* Q4 EARNINGS PER SHARE VIEW $1.93, REVENUE VIEW $3.46 BILLION -- THOMSON REUTERS I/B/E/S \n* REAFFIRMING 2020 TOTAL REVENUE AND ADJUSTED DILUTED EPS FINANCIAL TARGETS \n* FULL YEAR 2017 GAAP OPERATING MARGIN IS EXPECTED TO BE ABOUT 36 PERCENT \n* CELGENE - ESTIMATED GAAP EARNINGS PER SHARE FOR QUARTER & YEAR ENDED DEC 31, 2017 INCLUDE ESTIMATED IMPACT OF ABOUT $800 MILLION-ABOUT $1,300 MILLION DUE TO TAX CUTS AND JOBS ACT \n* ‍BASED ON GAAP, EPS FOR FULL-YEAR 2018 IS EXPECTED TO BE IN RANGE OF $6.58 TO $6.95​ Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-01-08T17:55:00.000+02:00", "crawled": "2018-01-08T18:11:11.001+02:00", "highlightTitle": ""}